Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 7, 2014, Pages 1313-1320

  Fülöp, Péter ^a   Seres, Ildikó ^a   Lorincz, Hajnalka ^a   Harangi, Mariann ^a   Somodi, Sándor ^a   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Adiponectin; Chemerin; Inflammation; Leptin; Obesity; Oxidized low density lipoprotein; Paraoxonase 1

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; CHIMERIN; LEPTIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; OBESITY; OXIDATIVE STRESS; PATHOLOGY;

ADIPOKINES; ADIPONECTIN; ADIPOSE TISSUE; ARYLDIALKYLPHOSPHATASE; BIOMARKERS; CASE-CONTROL STUDIES; CHIMERIN PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LEPTIN; LIPOPROTEINS, LDL; OBESITY; OXIDATIVE STRESS;

EID: 84904974350     PISSN: 15821838     EISSN: 15824934     Source Type: Journal    
DOI: 10.1111/jcmm.12282     Document Type: Article

References (52)

1. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341: 1097-105.
2. Ntaios G, Gatselis NK, Makaritsis K, et al. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013; 227: 216-21.
3. Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med. 2010; 14: 70-8.
4. Kertész A, Bombicz M, Priksz D, et al. Adverse impact of diet-induced hypercholesterolemia on cardiovascular tissue homeostasis in a rabbit model: time-dependent changes in cardiac parameters. Int J Mol Sci. 2013; 14: 19086-108.
5. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148: 4687-94.
6. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282: 28175-88.
7. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003; 198: 977-85.
8. Roman AA, Parlee SD, Sinal CJ. Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine. 2012; 42: 243-51.
9. Jialal I, Devaraj S, Kaur H, et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab. 2013; 98: E514-7.
10. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009; 58: 2731-40.
11. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009; 94: 3085-8.
12. Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009; 161: 339-44.
13. Rouger L, Denis GR, Luangsay S, et al. ChemR23 knockout mice display mild obesity but no deficit in adipocyte differentiation. J Endocrinol. 2013; 219: 279-89.
14. Kloek C, Haq AK, Dunn SL, et al. Regulation of Jak kinases by intracellular leptin receptor sequences. J Biol Chem. 2002; 277: 41547-55.
15. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334: 292-5.
16. Moro C, Grauzam S, Ormezzano O, et al. Inhibition of cardiac leptin expression after infarction reduces subsequent dysfunction. J Cell Mol Med. 2011; 15: 1688-94.
17. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291: 1730-7.
18. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003; 148: 293-300.
19. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997; 272: 20963-6.
20. Luc G, Fruchart JC. Oxidation of lipoproteins and atherosclerosis. Am J Clin Nutr. 1991; 53: 206S-9S.
21. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000; 20: 2243-7.
22. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001; 103: 1955-60.
23. Bak I, Lekli I, Juhasz B, et al. Cardioprotective mechanisms of Prunus cerasus (sour cherry) seed extract against ischemia-reperfusion-induced damage in isolated rat hearts. Am J Physiol Heart Circ Physiol. 2006; 291: H1329-36.
24. Juhasz B, Kertész A, Balla J, et al. Cardioprotective effects of sour cherry seed extract (SCSE) on the hypercholesterolemic rabbit heart. Curr Pharm Des. 2013; 19: 6896-905.
25. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol. 2004; 15: 261-7.
26. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995; 96: 2882-91.
27. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998; 101: 1581-90.
28. Ng CJ, Wadleigh DJ, Gangopadhyay A. et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001; 276: 44444-9.
29. Kempster SL, Belteki G, Licence D, et al. Disruption of paraoxonase 3 impairs proliferation and antioxidant defenses in human A549 cells and causes embryonic lethality in mice. Am J Physiol Endocrinol Metab. 2012; 302: E103-7.
30. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006; 281: 7657-65.
31. Tang WH, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012; 32: 2803-12.
32. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol. 2011; 81: 337-44.
33. Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012; 4: 523-32.
34. Bajnok L, Seres I, Varga Z, et al. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes. 2008; 116: 592-9.
35. Koncsos P, Seres I, Harangi M, et al. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res. 2010; 67: 309-13.
36. Mackness B, Mackness MI, Arrol S, et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998; 423: 57-60.
37. Veiga L, Silva-Nunes J, Melão A, et al. Q192R polymorphism of the paraoxonase-1 gene as a risk factor for obesity in Portuguese women. Eur J Endocrinol. 2011; 164: 213-8.
38. Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013; 34: 389-97.
39. Soriguer F, Gutiérrez-Repiso C, Rubio-Martín E, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013; 98: 2318-25.
40. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
41. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med. 2012; 16: 1978-90.
42. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131-5.
43. Fatima SS, Bozaoglu K, Rehman R, et al. Elevated chemerin levels in pakistani men: an interrelation with metabolic syndrome phenotypes. PLoS ONE. 2013; 8. doi:10.1371/journal.pone.0057113.
44. Sztanek F, Seres I, Harangi M, et al. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant. 2012; 27: 2866-72.
45. Rainwater DL, Rutherford S, Dyer TD, et al. Determinants of variation in human serum paraoxonase activity. Heredity. 2009; 102: 147-54.
46. Cabana VG, Reardon CA, Feng N, et al. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res. 2003; 44: 780-92.
47. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999; 26: 892-904.
48. Döcke S, Lock JF, Birkenfeld AL, et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol. 2013; 169: 547-57.
49. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol. 2002; 147: 173-80.
50. Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med. 2008; 205: 2187-90.
51. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol. 2010; 72: 342-8.
52. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013; 4. doi:10.3389/fendo.2013.00071.